Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential. However, it’s worth remembering that analysts rarely issue sell ratings, partly because their firms often seek other business from the same companies they cover.
At StockStory, we look beyond the headlines with our independent analysis to determine whether these bullish calls are justified. Keeping that in mind, here are three stocks likely to meet or exceed Wall Street’s lofty expectations.
Alphabet (GOOGL)
Consensus Price Target: $432.83 (20.4% implied return)
Started by Stanford students Larry Page and Sergey Brin in a Menlo Park garage, Alphabet (NASDAQ: GOOGL) is the parent company of the eponymous Google Search engine, Google Cloud Platform, and YouTube.
What Makes GOOGL Stand Out?
- Alphabet’s dominant Google Search sits on the pantheon of the best businesses ever. This is reflected in its robust long-term revenue growth and elite operating margin.
- The company’s profit margins have become even higher over time, speaking to its scale advantages and operating efficiency not only in its core Search business but also in Google Cloud Platform and YouTube.
- Revenue growth and increasing operating margins are the key ingredients for strong EPS growth. Google has these, and when also factoring in its share repurchases, you can see why EPS has exploded over the long term.
Alphabet is trading at $359.49 per share, or 28.8x forward price-to-earnings. Is now a good time to buy? See for yourself in our full research report, it’s free.
ANI Pharmaceuticals (ANIP)
Consensus Price Target: $109.88 (27.7% implied return)
With a diverse portfolio of 116 pharmaceutical products and a growing rare disease platform, ANI Pharmaceuticals (NASDAQ: ANIP) develops, manufactures, and markets branded and generic prescription pharmaceuticals, with a focus on rare disease treatments.
Why Are We Fans of ANIP?
- Market share has increased this cycle as its 33.6% annual revenue growth over the last two years was exceptional
- Free cash flow margin jumped by 38.4 percentage points over the last five years, giving the company more resources to pursue growth initiatives, repurchase shares, or pay dividends
- Rising returns on capital show the company is starting to reap the benefits of its past investments
ANI Pharmaceuticals’s stock price of $86.03 implies a valuation ratio of 9.4x forward P/E. Is now the time to initiate a position? Find out in our full research report, it’s free.
California Resources (CRC)
Consensus Price Target: $82.45 (60.9% implied return)
Operating some of California's most productive oil fields including Elk Hills and Belridge, California Resources (NYSE: CRC) explores for and produces crude oil, natural gas, and natural gas liquids from fields across California.
Why Does CRC Stand Out?
- Annual revenue growth of 17.3% over the past five years was outstanding, reflecting market share gains this cycle
- Attractive asset base result in a stellar gross margin of 57.2%
- Strong free cash flow margin of 12.9% enables it to reinvest or return capital consistently
At $51.26 per share, California Resources trades at 7.7x forward P/E. Is now the right time to buy? See for yourself in our comprehensive research report, it’s free.
Stocks We Like Even More
ONE MORE THING: Top 6 Stocks for This Week. This market is separating quality stocks from expensive ones fast. AI is taking down whole sectors with no warning. In a rotation this fast, you need more than a list of good companies.
Our AI system flagged Palantir before it ran 1,662%. AppLovin before it ran 753%. Nvidia before it ran 1,178%. Each week it produces 6 new names that pass the same tests. Get Our Top 6 Stocks for Free HERE.
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today.
